Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
TriSalus Life Sciences, Inc. (TLSI)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$3.89+11.78%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for TLSI yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Achieve FDA clearance for TriNav Advance | It is working to get FDA clearance for TriNav Advance. | Recovered | FDA clearance not achieved by end of 2026 | FDA clearance achieved vs target by end of 2026 News confirms FDA clearance for TriNav Advance on 2026-09-22, with analysts raising price targets. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 1 of 2 supplied quarters. Management reported: “– September 22, 2026 – TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard-of-care therapies and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for TriNav ® Advance, the newest addition to its Pressure-Enabled Drug Delivery™ (PEDD) portfolio.” “Our updated revenue outlook reflects the lower Q1 revenue from the commercial expansion and the delayed FDA clearance timing for TriNav Advance, our next-generation device which extends PEDD capability to small distal vessels via microcatheter.” |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 10, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth business with a healthcare-sector tailwind, not yet a proven earnings compounder. The long-term thesis is in a watch state: revenue is growing, but recent financial performance is weak and operating losses remain high.
The valuation is tagged as justified, with a durable premium of 1.7 times versus peers. The expectations gap is negative, but model confidence is low, so the evidence on what the market assumes is limited.
Near term, revenue growth and the TriNav Advance FDA clearance support commercial expansion, and management reaffirmed its 2026 revenue guidance. However, operating losses widened in the second quarter as sales and marketing costs rose, despite a small improvement in gross margin; risk has also shifted to high after an earnings miss.
The multi-year view depends on whether wider commercial reach and the expanded device portfolio can translate into stronger results while costs are managed. Near term, guidance changes and a weakening jobs backdrop are risks, while continued strong results from healthcare bellwethers could support sector momentum.
Over the next one to three years, TLSI has a credible expansion story but limited proof of improving profitability, with high risk and a watch-state thesis. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Operating income improves from -$8.41 million in 2026-Q1 | A primary condition in TriSalus Life Sciences, Inc.'s published investment case. The stated target is Operating loss narrows vs -$8.41 million in 2026-Q1. | Intact | Operating loss worsens beyond -$8.41 million over next 4 quarters | Operating income: $-9.813M FY2026-Q2; GAAP. Published target: Operating loss narrows vs -$8.41 million in 2026-Q1. Target period is not explicitly aligned with this observation. Aug 6, 2026-9,813,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “The increase in operating losses was primarily driven by higher sales and marketing expenses related to our investment in marketing and our sales organization expansion, partially offset by improved gross margins, lower research and development and lower general and administrative expenses.” “The increase in operating losses was primarily driven by higher sales and marketing expenses related to our commercial expansion and an increase in non-cash stock-based compensation expense, partially offset by improved gross margins.” Operating income was $-9.813 million in 2026-Q2. Delivery assessment Nov 4, 2026 |
Revenue grows to at least $54 million in 2026 | A primary condition in TriSalus Life Sciences, Inc.'s published investment case. The stated target is >= $54 million. | Intact | Revenue falls below $54 million in FY26 | Revenue: $11.407M FY2026-Q2; GAAP. Published target: >= $54 million. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 202611,407,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “2026 Financial Guidance The Company is maintaining its full-year 2026 revenue guidance of $54 million to $57 million, consistent with the range set in the first quarter and representing growth of 19% to 26% compared to full year 2025.” “Financial Results for Q2 2026 • Revenue from the sale of the TriNav system was $11.4 million for the three months ended June 30, 2026, which was relatively consistent with the prior comparative period with an increase of 1.7% compared to the same period in 2025.” Revenue was $11.407 million in 2026-Q2. Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.14 → $-0.26 · observed estimates
$0.08B → $0.07B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.14 | $79,262,500 | 3 / 3 |
| 2026-07-25 | $-0.14 | $79,262,500 | 4 / 4 |
| 2026-07-26 | $-0.14 | $79,262,500 | 4 / 4 |
| 2026-07-27 | $-0.14 | $79,262,500 | 3 / 3 |
| 2026-07-28 | $-0.14 | $79,262,500 | 4 / 4 |
| 2026-07-29 | $-0.14 | $79,262,500 | 3 / 3 |
| 2026-07-30 | $-0.14 | $79,262,500 | 3 / 3 |
| 2026-07-31 | $-0.14 | $79,262,500 | 4 / 4 |
| 2026-08-01 | $-0.14 | $79,262,500 | 3 / 3 |
| 2026-08-02 | $-0.14 | $79,262,500 | 4 / 4 |
| 2026-08-03 | $-0.14 | $79,262,500 | 4 / 4 |
| 2026-08-04 | $-0.14 | $79,262,500 | 4 / 4 |
| 2026-08-05 | $-0.14 | $79,262,500 | 4 / 4 |
| 2026-08-06 | $-0.14 | $79,262,500 | 4 / 4 |
| 2026-08-08 | $-0.14 | $79,262,500 | 3 / 3 |
| 2026-08-09 | $-0.14 | $79,262,500 | 4 / 4 |
| 2026-08-10 | $-0.14 | $79,262,500 | 4 / 4 |
| 2026-08-12 | $-0.14 | $79,262,500 | 3 / 3 |
| 2026-08-13 | $-0.18 | $73,548,500 | 4 / 4 |
| 2026-08-14 | $-0.14 | $79,262,500 | 3 / 3 |
| 2026-08-15 | $-0.14 | $79,262,500 | 3 / 3 |
| 2026-08-16 | $-0.14 | $79,262,500 | 3 / 3 |
| 2026-08-17 | $-0.14 | $79,262,500 | 3 / 3 |
| 2026-08-18 | $-0.14 | $79,262,500 | 3 / 3 |
| 2026-08-19 | $-0.14 | $79,262,500 | 3 / 3 |
| 2026-08-20 | $-0.26 | $73,548,500 | 3 / 3 |
| 2026-08-21 | $-0.26 | $73,548,500 | 3 / 3 |
| 2026-08-22 | $-0.26 | $73,548,500 | 3 / 3 |
| 2026-08-23 | $-0.26 | $73,548,500 | 3 / 3 |
| 2026-08-24 | $-0.26 | $73,548,500 | 3 / 3 |
| 2026-08-25 | $-0.26 | $73,548,500 | 3 / 3 |
| 2026-08-26 | $-0.26 | $73,548,500 | 3 / 3 |
| 2026-08-27 | $-0.26 | $73,548,500 | 3 / 3 |
| 2026-08-28 | $-0.26 | $73,545,916 | 3 / 3 |
| 2026-08-29 | $-0.26 | $73,545,916 | 3 / 3 |
| 2026-08-30 | $-0.26 | $73,545,916 | 3 / 3 |
| 2026-08-31 | $-0.26 | $73,545,916 | 3 / 3 |
| 2026-09-01 | $-0.26 | $73,545,916 | 3 / 3 |
| 2026-09-02 | $-0.26 | $73,545,916 | 3 / 3 |
| 2026-09-03 | $-0.26 | $73,545,916 | 3 / 3 |
| 2026-09-04 | $-0.26 | $73,545,916 | 3 / 3 |
| 2026-09-05 | $-0.26 | $73,545,916 | 3 / 3 |
| 2026-09-06 | $-0.26 | $73,545,916 | 3 / 3 |
| 2026-09-07 | $-0.26 | $73,545,916 | 3 / 3 |
| 2026-09-08 | $-0.26 | $73,545,916 | 3 / 3 |
| 2026-09-09 | $-0.26 | $73,545,916 | 3 / 3 |
| 2026-09-10 | $-0.26 | $73,545,916 | 3 / 3 |
| 2026-09-11 | $-0.26 | $74,391,533 | 3 / 3 |
| 2026-09-12 | $-0.26 | $74,391,533 | 3 / 3 |
| 2026-09-13 | $-0.26 | $74,391,533 | 3 / 3 |
| 2026-09-14 | $-0.26 | $74,391,533 | 3 / 3 |
| 2026-09-15 | $-0.26 | $74,391,533 | 3 / 3 |
| 2026-09-16 | $-0.26 | $74,391,533 | 3 / 3 |
| 2026-09-17 | $-0.26 | $74,391,533 | 3 / 3 |
| 2026-09-18 | $-0.26 | $74,391,533 | 3 / 3 |
| 2026-09-19 | $-0.26 | $74,391,533 | 3 / 3 |
| 2026-09-20 | $-0.26 | $74,391,533 | 3 / 3 |
| 2026-09-21 | $-0.26 | $74,391,533 | 3 / 3 |
| 2026-09-22 | $-0.26 | $74,391,533 | 3 / 3 |
| 2026-09-23 | $-0.26 | $74,391,533 | 3 / 3 |
| 2026-09-24 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-09-25 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-09-26 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-09-27 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-09-28 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-09-29 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-09-30 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-10-01 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-10-02 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-10-03 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-10-04 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-10-05 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-10-06 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-10-07 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-10-08 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-10-09 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-10-10 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-10-11 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-10-12 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-10-13 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-10-14 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-10-15 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-10-16 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-10-17 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-10-18 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-10-19 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-10-20 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-10-21 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-10-22 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-10-23 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-10-24 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-10-25 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-10-26 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-10-27 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-10-28 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-10-29 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-10-30 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-10-31 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-11-01 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-11-02 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-11-03 | $-0.26 | $74,506,340 | 3 / 3 |
| 2026-11-04 | $-0.26 | $74,506,340 | 3 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 5 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.